首页 > 市场调查报告书 > 製药

药物开发开发业务受託机关

市场调查报告书

商品编码

1676206

全球大分子药物 CDMO 市场研究报告 - 产业分析、规模、份额、成长、趋势和预测 2025 年至 2033 年

Global Large Molecule Drug Substance CDMO Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

出版日期: 2025年03月01日 | 出版商:

Value Market Research | 英文 157 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球大分子药物 Cdmo 市场规模预计将从 2024 年的 208.2 亿美元增长到 2033 年的 485.8 亿美元，在 2026 年至 2033 年的预测期内呈现 9.87% 的强劲年复合成长率(CAGR)。

随着生物製剂的日益复杂以及对创新疗法的需求不断增长，大分子药物合约开发和製造组织 (CDMO) 市场即将大幅扩张。随着製药公司转向生物製剂，对专业製造能力的需求变得至关重要。该市场的特点是从传统的小分子药物转向大分子治疗剂，包括单株抗体、重组蛋白和基因疗法。这些产品的复杂性质需要先进的製造流程、严格的品质控制和法规遵循性，而 CDMO 具有独特的优势来提供这些服务。

此外，个人化医疗的兴起正在催化对客製化生物疗法的需求，进一步推动大分子药物 CDMO 市场的成长。随着医疗保健系统越来越多地采用精准医疗方法，大规模生产客製化生物製剂的能力将成为製药公司的关键差异化因素。投资于一次性系统和持续製造等尖端技术的 CDMO 可能会获得竞争优势。此外，生物製药公司和 CDMO 之间的策略合作伙伴关係将增强创新并加快新疗法的开发，确保市场保持活力并响应新兴的医疗保健需求。

大分子药物 CDMO 的全球格局也受到监管进步和对永续性日益关注的影响。随着监管机构简化生物製剂的审批流程，新疗法的上市时间将会缩短，为 CDMO 创造更灵活的环境。此外，在製造过程中融入永续实践不仅可以满足监管要求，而且还能满足消费者对环保医疗保健解决方案日益增长的需求。随着市场的发展，重视创新、协作和永续性的 CDMO 将在这个新兴领域占据有利地位并蓬勃发展。

我们的报告经过精心製作，为客户提供有关各个行业和市场的全面且可操作的见解。每份报告都包含几个关键部分，以确保彻底了解市场格局：

市场概览：市场的详细介绍，包括定义、分类和行业现状概述。

市场动态：深入分析影响市场成长的关键驱动因素、限制因素、机会与挑战。本节探讨技术进步、监管变化和新兴趋势等因素。

細項分析：根据产品类型、应用、最终用户和地理位置等标准将市场细分为不同的细分市场。该分析强调了每个部分的表现和潜力。

竞争格局：对主要市场参与者的全面评估，包括其市场份额、产品组合、策略倡议和财务表现。本节深入介绍领先公司的竞争动态和关键策略。

市场预测：根据历史资料和当前市场状况，预测特定时期内的市场规模和成长趋势。这包括定量分析和图形表示来说明未来的市场轨迹。

区域分析：评估不同地理区域的市场表现，确定关键市场和区域趋势。这有助于了解区域市场动态和机会。

新兴趋势与机会：识别当前和新兴的市场趋势、技术创新和潜在投资领域。本节提供未来市场发展和成长前景的见解。

区域展望
介绍
北美销售分析
- 概述、历史和预测数据销售分析
- 北美各细分市场销售分析
- 北美各国销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概述、历史和预测数据销售分析
- 欧洲各细分市场销售分析
- 欧洲各国销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概述、历史和预测数据销售分析
- 亚太地区分部销售分析
- 亚太地区国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概述、历史和预测数据销售分析
- 拉丁美洲各细分市场销售分析
- 拉丁美洲各国销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概述、历史和预测数据销售分析
- 中东和非洲分部销售分析
- 中东和非洲国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东和非洲其他地区销售分析

第 9 章：大分子药物 CDMO 公司的竞争格局

大分子药物CDMO市场竞争
伙伴关係/合作/协议
合併与收购
新产品发布
其他进展

第十章：公司简介

顶级公司市占率分析
市场集中度
Eurofins Scientific

公司概况
公司收入
产品
最新动态

WuXi Biologics

公司概况
公司收入
产品
最新动态

Samsung Biologics

公司概况
公司收入
产品
最新动态

Catalent Inc.

公司概况
公司收入
产品
最新动态

Rentschler Biopharma SE

公司概况
公司收入
产品
最新动态

AGC Biologics

公司概况
公司收入
产品
最新动态

Recipharm AB

公司概况
公司收入
产品
最新动态

Siegfried Holding AG

公司概况
公司收入
产品
最新动态

Boehringer Ingelheim

公司概况
公司收入
产品
最新动态

FUJIFILM Diosynth Biotechnologies

公司概况
公司收入
产品
最新动态

注意 - 在公司简介中，财务细节和最新发展取决于可用性，对于私人公司，可能不予涵盖

简介目录图表

Product Code: VMR112110346

Global Large Molecule Drug Substance Cdmo Market size is anticipated to grow from USD 20.82 Billion in 2024 to USD 48.58 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 9.87% during the forecast period of 2026 to 2033.

The Large Molecule Drug Substance Contract Development and Manufacturing Organization (CDMO) market is poised for significant expansion, driven by the increasing complexity of biologics and the growing demand for innovative therapies. As pharmaceutical companies pivot towards biologics, the need for specialized manufacturing capabilities becomes paramount. This market is characterized by a shift from traditional small-molecule drugs to large-molecule therapeutics, including monoclonal antibodies, recombinant proteins, and gene therapies. The intricate nature of these products necessitates advanced manufacturing processes, stringent quality control, and regulatory compliance, which CDMOs are uniquely positioned to provide.

Moreover, the rise of personalized medicine is catalyzing the demand for tailored biologic therapies, further propelling the growth of the Large Molecule Drug Substance CDMO market. As healthcare systems increasingly adopt precision medicine approaches, the ability to produce customized biologics at scale will be a critical differentiator for pharmaceutical companies. CDMOs that invest in cutting-edge technologies, such as single-use systems and continuous manufacturing, will likely gain a competitive edge. Additionally, strategic partnerships between biopharmaceutical companies and CDMOs will enhance innovation and expedite the development of novel therapies, ensuring that the market remains dynamic and responsive to emerging healthcare needs.

The global landscape for Large Molecule Drug Substance CDMOs is also influenced by regulatory advancements and the increasing focus on sustainability. As regulatory bodies streamline approval processes for biologics, the time-to-market for new therapies will decrease, fostering a more agile environment for CDMOs. Furthermore, the integration of sustainable practices in manufacturing processes will not only meet regulatory requirements but also align with the growing consumer demand for environmentally responsible healthcare solutions. As the market evolves, CDMOs that prioritize innovation, collaboration, and sustainability will be well-positioned to thrive in this burgeoning sector.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Service

Contract Manufacturing
Contract Development

By Source

Mammalian
Microbial
Others

By End-User

Biotech Companies
CRO
Other
COMPANIES PROFILED
Eurofins Scientific
WuXi Biologics
Samsung Biologics
Catalent Inc.
Rentschler Biopharma SE
AGC Biologics
Recipharm AB
Siegfried Holding AG
Boehringer Ingelheim
FUJIFILM Diosynth Biotechnologies
The above list can be customized.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. LARGE MOLECULE DRUG SUBSTANCE CDMO INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porters Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Service
- 3.7.2 Market Attractiveness Analysis By Source
- 3.7.3 Market Attractiveness Analysis By End-User
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET ANALYSIS BY SERVICE

5.1. Overview By Service
5.2. Historical and Forecast Data Analysis By Service
5.3. Contract Manufacturing Historic and Forecast Sales By Regions
5.4. Contract Development Historic and Forecast Sales By Regions

6. GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET ANALYSIS BY SOURCE

6.1. Overview By Source
6.2. Historical and Forecast Data Analysis By Source
6.3. Mammalian Historic and Forecast Sales By Regions
6.4. Microbial Historic and Forecast Sales By Regions
6.5. Others Historic and Forecast Sales By Regions

7. GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET ANALYSIS BY END-USER

7.1. Overview By End-User
7.2. Historical and Forecast Data Analysis By End-User
7.3. Biotech Companies Historic and Forecast Sales By Regions
7.4. CRO Historic and Forecast Sales By Regions
7.5. Other Historic and Forecast Sales By Regions

8. GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE LARGE MOLECULE DRUG SUBSTANCE CDMO COMPANIES

9.1. Large Molecule Drug Substance CDMO Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF LARGE MOLECULE DRUG SUBSTANCE CDMO INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Eurofins Scientific
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. WuXi Biologics
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Samsung Biologics
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Catalent Inc.
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Rentschler Biopharma SE
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. AGC Biologics
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Recipharm AB
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Siegfried Holding AG
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Boehringer Ingelheim
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. FUJIFILM Diosynth Biotechnologies
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

简介目录图表

LIST OF TABLES

Market Snapshot
Drivers: Impact Analysis
Restraints: Impact Analysis
List of Raw Material
List of Raw Material Manufactures
Analysis By Service (USD MN)
Contract Manufacturing Market Sales By Geography (USD MN)
Contract Development Market Sales By Geography (USD MN)
Analysis By Source (USD MN)
Mammalian Market Sales By Geography (USD MN)
Microbial Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Analysis By End-User (USD MN)
Biotech Companies Market Sales By Geography (USD MN)
CRO Market Sales By Geography (USD MN)
Other Market Sales By Geography (USD MN)
Global Large Molecule Drug Substance CDMO Market Sales By Geography (USD MN)
North America Market Analysis (USD MN)
United States Market Analysis (USD MN)
Canada Market Analysis (USD MN)
Mexico Market Analysis (USD MN)
Europe Market Analysis (USD MN)
Europe Market Estimate By Country (USD MN)
United Kingdom Market Analysis (USD MN)
France Market Analysis (USD MN)
Germany Market Analysis (USD MN)
Italy Market Analysis (USD MN)
Russia Market Analysis (USD MN)
Spain Market Analysis (USD MN)
Rest of Europe Market Analysis (USD MN)
Asia Pacific Market Analysis (USD MN)
China Market Analysis (USD MN)
Japan Market Analysis (USD MN)
India Market Analysis (USD MN)
South Korea Market Analysis (USD MN)
Australia Market Analysis (USD MN)
South East Asia Market Analysis (USD MN)
Rest of Asia Pacific Market Analysis (USD MN)
Latin America Market Analysis (USD MN)
Brazil Market Analysis (USD MN)
Argentina Market Analysis (USD MN)
Peru Market Analysis (USD MN)
Chile Market Analysis (USD MN)
Rest of Latin America Market Analysis (USD MN)
Middle East & Africa Market Analysis (USD MN)
Saudi Arabia Market Analysis (USD MN)
UAE Market Analysis (USD MN)
Israel Market Analysis (USD MN)
South Africa Market Analysis (USD MN)
Rest of Middle East and Africa Market Analysis (USD MN)
Partnership/Collaboration/Agreement
Mergers And Acquisition

LIST OF FIGURES

Research Scope of Large Molecule Drug Substance CDMO Report
Market Research Process
Market Research Methodology
Global Large Molecule Drug Substance CDMO Market Size, By Region (USD MN)
Porters Five Forces Analysis
Market Attractiveness Analysis By Service
Market Attractiveness Analysis By Source
Market Attractiveness Analysis By End-User
Market Attractiveness Analysis By Region
Value Chain Analysis
Global Market Analysis By Service (USD MN)
Contract Manufacturing Market Sales By Geography (USD MN)
Contract Development Market Sales By Geography (USD MN)
Global Market Analysis By Source (USD MN)
Mammalian Market Sales By Geography (USD MN)
Microbial Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Global Market Analysis By End-User (USD MN)
Biotech Companies Market Sales By Geography (USD MN)
CRO Market Sales By Geography (USD MN)
Other Market Sales By Geography (USD MN)
Global Market Sales (USD MN)
North America Market Sales (USD MN)
Europe Market Sales (USD MN)
Asia Pacific Market Sales (USD MN)
Latin America Market Sales (USD MN)
Middle East & Africa Market Sales (USD MN)
Recent Development in Industry
Top Company Market Share Analysis
Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.